BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9864171)

  • 1. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells.
    Bazarbachi A; El-Sabban ME; Nasr R; Quignon F; Awaraji C; Kersual J; Dianoux L; Zermati Y; Haidar JH; Hermine O; de Thé H
    Blood; 1999 Jan; 93(1):278-83. PubMed ID: 9864171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.
    El-Sabban ME; Nasr R; Dbaibo G; Hermine O; Abboushi N; Quignon F; Ameisen JC; Bex F; de Thé H; Bazarbachi A
    Blood; 2000 Oct; 96(8):2849-55. PubMed ID: 11023521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells.
    Darwiche N; El-Sabban M; Bazzi R; Nasr R; Al-Hashimi S; Hermine O; de Thé H; Bazarbachi A
    Hematol J; 2001; 2(2):127-35. PubMed ID: 11424005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines.
    Ishitsuka K; Hanada S; Uozumi K; Utsunomiya A; Arima T
    Leuk Lymphoma; 2000 May; 37(5-6):649-55. PubMed ID: 11042529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.
    Brown M; Bellon M; Nicot C
    Blood; 2007 Feb; 109(4):1653-9. PubMed ID: 17077332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha.
    Mahieux R; Hermine O
    Leuk Lymphoma; 2005 Mar; 46(3):347-55. PubMed ID: 15621824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation.
    Ishitsuka K; Ikeda R; Utsunomiya A; Uozumi K; Hanada S; Suzuki S; Takeuchi S; Takatsuka Y; Takeshita T; Ohno N; Arima T
    Leuk Lymphoma; 2002 May; 43(5):1107-14. PubMed ID: 12148893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma.
    Bazarbachi A; Nasr R; El-Sabban ME; Mahé A; Mahieux R; Gessain A; Darwiche N; Dbaibo G; Kersual J; Zermati Y; Dianoux L; Chelbi-Alix MK; de Thé H; Hermine O
    Leukemia; 2000 Apr; 14(4):716-21. PubMed ID: 10764160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage.
    Mahieux R; Pise-Masison C; Gessain A; Brady JN; Olivier R; Perret E; Misteli T; Nicot C
    Blood; 2001 Dec; 98(13):3762-9. PubMed ID: 11739184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells.
    Nasr R; Rosenwald A; El-Sabban ME; Arnulf B; Zalloua P; Lepelletier Y; Bex F; Hermine O; Staudt L; de Thé H; Bazarbachi A
    Blood; 2003 Jun; 101(11):4576-82. PubMed ID: 12560223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells.
    Kinpara S; Kijiyama M; Takamori A; Hasegawa A; Sasada A; Masuda T; Tanaka Y; Utsunomiya A; Kannagi M
    Retrovirology; 2013 May; 10():52. PubMed ID: 23688327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (Saimiri sciureus).
    Heraud JM; Mortreux F; Merien F; Contamin H; Mahieux R; Pouliquen JF; Wattel E; Gessain A; de Thé H; Bazarbachi A; Hermine O; Kazanji M
    Antiviral Res; 2006 Jul; 70(3):132-9. PubMed ID: 16540180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
    Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
    Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
    Kchour G; Tarhini M; Kooshyar MM; El Hajj H; Wattel E; Mahmoudi M; Hatoum H; Rahimi H; Maleki M; Rafatpanah H; Rezaee SA; Yazdi MT; Shirdel A; de Thé H; Hermine O; Farid R; Bazarbachi A
    Blood; 2009 Jun; 113(26):6528-32. PubMed ID: 19411628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.
    Dassouki Z; Sahin U; El Hajj H; Jollivet F; Kfoury Y; Lallemand-Breitenbach V; Hermine O; de Thé H; Bazarbachi A
    Blood; 2015 Jan; 125(3):474-82. PubMed ID: 25395419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
    Hermine O; Dombret H; Poupon J; Arnulf B; Lefrère F; Rousselot P; Damaj G; Delarue R; Fermand JP; Brouet JC; Degos L; Varet B; de Thé H; Bazarbachi A
    Hematol J; 2004; 5(2):130-4. PubMed ID: 15048063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.
    Nasr R; Marçais A; Hermine O; Bazarbachi A
    Methods Mol Biol; 2017; 1582():197-216. PubMed ID: 28357672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide inhibits human t cell-lymphotropic virus-1-induced syncytiums by down-regulating gp46.
    Nabeshi H; Yoshikawa T; Kamada H; Shibata H; Sugita T; Abe Y; Nagano K; Nomura T; Minowa K; Yamashita T; Itoh N; Yoshioka Y; Tsunoda S; Tsutsumi Y
    Biol Pharm Bull; 2009 Jul; 32(7):1286-8. PubMed ID: 19571400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids.
    Ishitsuka K; Hanada S; Suzuki S; Utsunomiya A; Chyuman Y; Takeuchi S; Takeshita T; Shimotakahara S; Uozumi K; Makino T; Arima T
    Br J Haematol; 1998 Dec; 103(3):721-8. PubMed ID: 9858223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation.
    Yuen CK; Chan CP; Fung SY; Wang PH; Wong WM; Tang HV; Yuen KS; Chan CP; Jin DY; Kok KH
    J Virol; 2016 Apr; 90(8):3902-3912. PubMed ID: 26819312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.